28336141|t|The discovery of potent and selective kynurenine 3-monooxygenase inhibitors for the treatment of acute pancreatitis
28336141|a|A series of potent, competitive and highly selective kynurenine monooxygenase inhibitors have been discovered via a substrate -based approach for the treatment of acute pancreatitis. The lead compound demonstrated good cellular potency and clear pharmacodynamic activity in vivo.
28336141	4	13	discovery	T052	C1880355
28336141	17	23	potent	T080	C0205556
28336141	28	37	selective	T080	C0205556
28336141	38	64	kynurenine 3-monooxygenase	T116,T126	C0064449
28336141	65	75	inhibitors	T121	C0014432
28336141	84	93	treatment	T061	C0087111
28336141	97	115	acute pancreatitis	T047	C0001339
28336141	118	124	series	T081	C0205549
28336141	128	134	potent	T080	C0205556
28336141	136	147	competitive	T080	C0205556
28336141	152	158	highly	T080	C0205250
28336141	159	168	selective	T080	C0205556
28336141	169	193	kynurenine monooxygenase	T116,T126	C0064449
28336141	194	204	inhibitors	T121	C0014432
28336141	215	225	discovered	T052	C1880355
28336141	232	241	substrate	T167	C3891814
28336141	249	257	approach	T082	C0449445
28336141	266	275	treatment	T061	C0087111
28336141	279	297	acute pancreatitis	T047	C0001339
28336141	303	307	lead	T169	C1522538
28336141	308	316	compound	T103	C1706082
28336141	330	334	good	T080	C0205170
28336141	335	343	cellular	T025	C0007634
28336141	344	351	potency	T080	C0205556
28336141	362	377	pharmacodynamic	T038	C0851347
28336141	378	386	activity	T052	C0441655
28336141	387	394	in vivo	T082	C1515655